concurrent chemotherapy and radiation. They found that although acute toxicities (esophagitis and neutropenia) were higher in older patients, no differences were seen in long-term toxicity or overall survival based on age. In a similar analysis, Schild et al
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III and Arti Hurria
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer and Hema Sundar
was also active in patients with Richter's transformation (n=30), resulting in an ORR of 43% (27% CR), and the 1-year OS rate was 28%. 30 However, it was associated with significant toxicity (grade 3 neutropenia was the most common hematologic
Andrew D. Zelenetz
otherwise specified, angioimmunoblastic T-cell lymphoma, and sALCL (ALK1-negative). The most common treatment-related toxicities were nausea, vomiting, diarrhea, infection, asthenia, thrombocytopenia, and neutropenia. Cardiac toxicity was minimal (6
Presenter : Eunice S. Wang
secondary AML.” One clinical caveat is that rates of myelosuppression and febrile neutropenia with infections were significantly higher for the combination regimen than for azacitidine alone, with many patients requiring close monitoring and frequent
Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer and Maoko Naganuma
neutropenia (70%), thrombocytopenia (45%), anemia (18%), and febrile neutropenia (15%). 17 Lenalidomide was administered using different dosing schedules in these earlier studies. In one study, patients initially received lenalidomide at the 25-mg-daily dose
Stephen Harnicar
monitor for and manage toxicities associated with imatinib. A CBC count should be performed weekly for the first month, every 2 weeks for the second month, and periodically thereafter (e.g., every 2-3 months). Hematologic toxicities, including neutropenia
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer and Deborah A. Freedman-Cass
itself (eg, hypogammaglobulinemia in chronic lymphocytic leukemia or multiple myeloma). 54 – 58 In particular, chemotherapy can cause neutropenia, a major risk factor for the development of infections. 59 The frequency and severity of infection are
Armin Rashidi and Nancy L. Bartlett
20 months, and the median PFS for all patients was 5.6 months (21.7 months for those who achieved a CR). The most common adverse event was peripheral sensory neuropathy (42%) and the most common grade 3 to 4 adverse event was neutropenia (20%). In
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar and Leonard B. Saltz
) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions
Saurabh Rajguru and Brad S. Kahl
PFS was just 4 months, but the median response duration was 16.6 months, suggesting substantial clinical benefit in patients responding to treatment. The most common grade 3/4 AEs were neutropenia (43%) and thrombocytopenia (27%), with 34% and 31% of
